Medicare Advantage
CMS Issues Final Rule for CY 2027 Medicare Advantage, Prescription Drug Plans and 2027 MA Rate announcement.
The Centers for Medicare & Medicaid Services (CMS) April 6 released the Medicare Advantage and Part D Rate Announcement for calendar year 2027.
The Centers for Medicare & Medicaid Services April 2 released a final rule on policy and technical changes to Medicare Advantage, the Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly for contract year 2027.
The Centers for Medicare & Medicaid Services March 30 announced that C2C Innovative Solutions will replace Maximus in reviewing and processing appeals of adverse organization determinations and reconsiderations made by Medicare Advantage plans as of May 1.
CMS accepting comments on data collection requirements for Medicare Advantage plans, Part D sponsors
The Centers for Medicare & Medicaid Services is seeking comments by May 11 on its proposed revisions to data reporting requirements for Medicare Advantage and Part D plans, according to a Paperwork Reduction Act listing.
The Joint Economic Committee March 10 released a report that found Medicare Part B premiums rose last year due to Medicare Advantage overpayments.
A JAMA study published Feb. 18 found that 10% of Medicare Advantage beneficiaries — approximately 2.9 million — have needed to find other health coverage in 2026 due to MA plans leaving the market.
The Senate Special Committee on Aging held a hearing Feb. 11 on issues impacting physician burnout.
More than 34.1 million Americans were enrolled in a Medicare Advantage plan in 2025, accounting for 54% of all Medicare beneficiaries. We have seen enrollment in MA plans increase significantly over the past two decades, and the Congressional Budget Office projects that MA enrollment will continue…
A KFF analysis released Jan. 28 found that Medicare Advantage insurers made nearly 53 million prior authorization determinations in 2024, an increase from 49.8 million in 2023.